Carl Zeiss Meditec

Carl Zeiss Meditec has received 510(k) clearance from the US FDA for ZEISS CLINIC 360, a cloud- and browser-based software that consolidates diagnostic imaging data, EMR, and practice management systems into a unified patient view. The solution integrates data from ZEISS devices and DICOM-capable third-party devices and offers tools for monitoring glaucoma progression, trend analysis, and case/report exchange via “ZEISS Collaborative Care.” ZEISS CLINIC 360 will be available by subscription in the US from early fall 2026; ZEISS FORUM will remain available for users who prefer on-premise solutions. The product is not approved for use in humans in the EU. » More on de.investing.com

Carl Zeiss Meditec reported Q3 earnings per share of $0.54 and revenue of $562.7 million, both above consensus estimates, but continued to face margin pressure with an adjusted EBITA margin of 8.0%. Nine-month revenue fell 2.2% and the ophthalmology business—particularly in China—remained weak, while microsurgery grew. Management confirmed the full-year guidance of EUR 2.2–2.5 billion in revenue and an adjusted EBITA margin of 8–10%, but expects revenue to be at the lower end of the range. The stock reacted only modestly in premarket trading as investors weighed the stronger results against the uncertain growth and margin backdrop. » More on de.investing.com

The Carl Zeiss Meditec share plunged significantly after the publication of current business figures and was about 7.7% lower in the morning at around €27.96; the year-to-date loss is roughly 30%. Weaker business in China and unfavorable exchange rates were burdensome; revenue fell by nearly 3% and adjusted EBITA collapsed by almost 30%. JPMorgan rated the third quarter (excluding customs refunds) as below expectations and considers it likely that the company will end up at the lower end of its full-year targets. » More on finanzen.net